indacaterol and Airway-Obstruction

indacaterol has been researched along with Airway-Obstruction* in 1 studies

Other Studies

1 other study(ies) available for indacaterol and Airway-Obstruction

Article	Year
[Novel controllers of airway obstruction in COPD patients]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 30, Issue:175 For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency. The once-daily dose administration is an important step which may allow to enhance of patients compliance. Novel long-acting bronchodilators--beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as indacaterol and carmoterol--are under clinical application for the treatment of COPD patients. Moreover, some new long-acting antimuscarinic agents (LAMA) (aclidinium, glycopyrrolate) and dual-action ultra LABA+LAMA combination products are under development. The main target of therapeutic research is to produce a dimmer molecule known as M3 antagonist-beta2 agonist (MABA) bronchodilators which will open the door for a new range of combination products. Topics: Airway Obstruction; Amphetamines; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Humans; Hydroxyquinolines; Indans; Muscarinic Antagonists; Patient Compliance; Pulmonary Disease, Chronic Obstructive; Quinolones	2011

Article

Year

[Novel controllers of airway obstruction in COPD patients].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 30, Issue:175

For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency. The once-daily dose administration is an important step which may allow to enhance of patients compliance. Novel long-acting bronchodilators--beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as indacaterol and carmoterol--are under clinical application for the treatment of COPD patients. Moreover, some new long-acting antimuscarinic agents (LAMA) (aclidinium, glycopyrrolate) and dual-action ultra LABA+LAMA combination products are under development. The main target of therapeutic research is to produce a dimmer molecule known as M3 antagonist-beta2 agonist (MABA) bronchodilators which will open the door for a new range of combination products.

Topics: Airway Obstruction; Amphetamines; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Humans; Hydroxyquinolines; Indans; Muscarinic Antagonists; Patient Compliance; Pulmonary Disease, Chronic Obstructive; Quinolones

2011